Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.66 |
| ▸ | F3 | P13726 | 4/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | USP7 | Q93009 | 1/20 | 0.66 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.66 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.66 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | TOP2A | P11388 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999783 | 1.00 | ALOX5 (0.71) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL1982238 | 1.00 | ALOX5 (0.71) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL29727541 | 1.00 | ALOX5 (0.71) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL12853085 | 1.00 | ALOX5 (0.71) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL6808508 | 0.92 | ALOX5 (0.70) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL12509509 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL398310 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL8339201 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL2895626 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL2895622 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514759-A1 | TRITERPENE DERIVATIVE, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CHRONIC HEPATITIS C | Meiji Seika Pharma Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120251492-A1 | TRITERPENE DERIVATIVE AND AGENT FOR PREVENTING OR TREATING CHRONIC HEPATITIS C | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| WO-2012015043-A1 | LIQUID PHARMACEUTICAL COMPOSITION | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 (JP) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011074608-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CHRONIC HEPATITIS C | 明治製菓株式会社 (JP) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251492-A1 | TRITERPENE DERIVATIVE AND AGENT FOR PREVENTING OR TREATING CHRONIC HEPATITIS C | NR1H3, CYP4A11, NR1H4 | ALOX5 338/4885PTPN1 2503/4885F3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.